Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) announced that it has completed the construction of an extensive library of full-length, fully human monoclonal antibodies (mAbs). Initial analysis indicates a potential diversity of more than one trillion unique mAbs. The company believes this makes its library the largest full-length, fully human antibody library available for drug discovery and development partnerships…

View original here: 
Sorrento Therapeutics Announces Completion Of Diverse Library Of Full-Length, Fully Human Antibodies

You may also like:

• Palos Community Hospital Physician Advances New Therapy In Cartilage Repair
• EBM IPA Selects MedAZ Electronic Health Record, Practice Management And Billing System For Member Physicians
• ‘New’ Prostate Cancer Treatment 100% Effective
• First ‘Genetic Map’ Of Han Chinese May Aid Search For Disease Susceptibility Genes
• Cal/OSHA Conducts 305 Heat Inspections; Continues To See Increased Compliance
• Nile Therapeutics CD-NP Clinical Program For Acute Heart Failure Released From Clinical Hold By FDA
• Human Anthrax Infections Reach 327 Cases In Bangladesh
• Amneal Announces FDA Approval For Spironolactone HCl Tablets
• FDA Issues Long List of Harmful Tobacco Components
• World’s Largest Meeting Of Ear, Nose And Throat Doctors To Convene In Boston Sept. 26-29, 2010